Asia Pacific Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Asia Pacific Osteoporosis Drugs Market
The Asia Pacific Osteoporosis Drugs Market would witness market growth of 5.6% CAGR during the forecast period (2020-2026). The Asia Pacific market is expected to rise in the coming years in a lucrative CAGR. The region's rapid growth is expected to be a result of steady R&D spending by the prominent actors and their attempts to market branded and generic medicine at a reasonably low price. The industry is expected to witness intense competition during the forecast period as a result of the increasing incorporation of collaborative strategies among key players to maintain a competitive position. High R&D investment, fusions, and acquisitions, and drug development agreements are the other strategies incorporated.
There has been a noticeable growth in people around the world's awareness of osteoporosis, which is a noticeable factor in the osteoporosis market. This recognition is primarily a result of numerous steps implemented across different programs and campaigns by public and private associations. For example, the International Foundation for Osteoporosis is an osteoporosis organization.
Due to the increase in R&D investment from major players in advanced novel bisphosphonate drugs, bisphosphonates acquired the major share in the osteoporosis market. Bisphosphonates are also widely used osteoporosis drugs, which stimulates market growth. However, the rank ligand inhibitor segment is expected to have the fastest growth rate during the forecast period, due to the fact that these drugs are used to treat bone metastases by acting as a chemoattractant to the bone for tumor cells that express its receptor, RANK. The RANKL-RANK pathway inhibition thus acts as an ideal treatment for bone metastasis.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Asia Pacific Osteoporosis Drugs Market Analysis
By Route of Administration
- Injectable and
- Other Route of Administration
By Drug Class
- Rank Ligand Inhibitors
- Parathyroid Hormone Therapy
- Selective Estrogen Inhibitors Modulator (SERM) and
- Other Drug Classes
- South Korea
- Rest of Asia Pacific
- Amgen, Inc.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Allergan PLC
- Eli Lilly and Company
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free